Welcome to our dedicated page for Foghorn Therapeutics SEC filings (Ticker: FHTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Foghorn Therapeutics Inc. filings document a clinical-stage biotechnology issuer with common stock listed on the Nasdaq Global Market under FHTX. The company’s current-event filings cover financial results, Regulation FD investor presentations, oncology pipeline disclosures for FHD-909 and selective CBP, EP300 and ARID1B degrader programs, and collaboration-related revenue.
Proxy and 8-K filings also address annual-meeting voting matters, board and executive governance, officer appointments, compensatory arrangements, material agreements, capital-structure disclosures and security-registration details tied to the company’s common stock and financing activity.
Foghorn Therapeutics Inc. reported Q2 2026 collaboration revenue of $16.1 million, up from $7.6 million a year earlier, driven largely by a $14.2 million cumulative catch-up adjustment on its Eli Lilly collaboration as the research term approaches scheduled expiration in December 2026. Research and development expenses were $18.5 million and general and administrative expenses $6.4 million, both lower than Q2 2025, reflecting reduced spending on Lilly-partnered programs, discontinued FHD‑286 activities and lower facility costs after relocating to Watertown, Massachusetts.
Net loss for the quarter narrowed to $7.2 million, or $0.10 per share, from $17.9 million, or $0.28 per share, in Q2 2025. For the first six months of 2026, revenue was $19.3 million and net loss $27.1 million. Cash, cash equivalents and marketable securities totaled $167.6 million as of June 30 2026, and management states this balance is expected to fund operating and capital needs for at least 12 months, though additional financing will be required over time to support ongoing development of the Gene Traffic Control® platform and pipeline, including the SMARCA2 program FHD‑909 being developed with Lilly.
In January 2026, Foghorn raised approximately $50.0 million in gross proceeds through a direct offering of common stock, pre‑funded warrants, and two series of equity‑classified warrants, while deferred revenue related to the Lilly collaboration was $229.8 million remaining to be recognized over the development period.
Foghorn Therapeutics reported Q2 2026 results alongside a broad pipeline update in chromatin biology. Lead asset FHD‑909, a first‑in‑class selective SMARCA2 inhibitor partnered with Lilly, is advancing through a first‑in‑human Phase 1 dose‑escalation trial focused on SMARCA4‑mutant non‑small cell lung cancer. Pending successful Phase 1 dose escalation, Foghorn and Lilly anticipate evaluating FHD‑909 in combination studies in NSCLC with pembrolizumab. Selective EP300 degraders for hematologic malignancies and prostate cancer and a selective CBP degrader (FHT‑171) for ER+ breast and EP300‑mutant cancers are progressing preclinically, with INDs targeted in 2027. A novel oral small molecule in immunology and inflammation and a first‑in‑class ARID1B degrader for ARID1A‑mutant solid tumors are also being advanced toward 2027 INDs, while the CBP program timeline has been delayed by an operational issue at a third‑party contract research organization.
Collaboration revenue for the quarter was $16.1 million versus $7.6 million a year earlier, driven by a cumulative catch‑up adjustment under the Lilly collaboration. Research and development expenses were $18.5 million and general and administrative expenses were $6.4 million. Net loss was $7.2 million compared with $17.9 million in Q2 2025. Cash, cash equivalents and marketable securities totaled $167.6 million at June 30, 2026, providing cash runway into the first half of 2028.
Foghorn Therapeutics Inc. director Thomas J. Lynch Jr. received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, conditioned on his continued service on the board of directors, and expire on June 23, 2036. Following this grant, he holds options for 28,000 underlying shares directly.
Foghorn Therapeutics Inc. director Stuart Duty received a grant of stock options to buy 28,000 shares of Common Stock at an exercise price of $4.08 per share. The options vest in full on the first anniversary of the grant date, subject to his continued board service, and expire on June 23, 2036. Following this grant, Duty holds 28,000 stock options directly.
Foghorn Therapeutics director Scott Biller received a stock option grant covering 28,000 shares of common stock at an exercise price of $4.08 per share. The option was granted as compensation and will vest in full on the first anniversary of the grant date, as long as he continues serving on the board of directors. Following this award, Biller holds 28,000 stock options directly.
Foghorn Therapeutics Inc. director Neil Gallagher received a grant of stock options as part of his compensation. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.08 per share. The options vest in full on the first anniversary of the grant date, as long as he continues serving on the board of directors. After this grant, he holds 28,000 stock options directly, which are scheduled to expire on June 23, 2036. This is a compensation-related award, not an open-market purchase or sale.
Foghorn Therapeutics director Michael Mendelsohn received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options were awarded as compensation and give him the right to buy shares at that price in the future.
The options vest in full on the first anniversary of the grant date, as long as he continues to serve on the board of directors. After this grant, he holds 28,000 stock options directly, with an expiration date in 2036, providing long-term equity-based incentives tied to the company’s share performance.
Foghorn Therapeutics Inc. director Ian F. Smith received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, contingent on his continued board service, and expire on June 23, 2036. Following this compensation award, Smith holds 28,000 options directly, and the filing reports no open-market buying or selling activity.
Foghorn Therapeutics Inc. director Simba Gill received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, subject to continued service on the board, and expire on June 23, 2036. Following this award, Gill holds 28,000 stock options directly.
Foghorn Therapeutics Inc. director Lynne B. Parshall received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $4.08 per share and expire on June 23, 2036. Following this grant, she holds 28,000 options directly. According to the terms, the option vests in full on the first anniversary of the grant date, assuming she continues to serve on the board of directors.